© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Anas Younes, MD, Chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the interim analysis of a study exploring the safety and efficacy of atezolizumab (Tecentriq) in combination with obinutuzumab (Gazya) and bendamustine in patients with previously untreated follicular lymphoma.